Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | HTR1B | P28222 | 1/20 | 0.36 |
| ▸ | NISCH | Q9Y2I1 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.32 |
| ▸ | TOP2A | P11388 | 1/20 | 0.30 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12724532 | 0.76 | — | — | |
| SCHEMBL2625319 | 0.71 | NOS3 (0.44) | NOS3NOS1NOS2HTR1DHTR1B | |
| SCHEMBL12701677 | 0.71 | ADRA2A (0.46) | NOS3NOS1NOS2NISCHGAA | |
| SCHEMBL7772486 | 0.71 | — | — | |
| SCHEMBL709292 | 0.67 | NOS3 (0.40) | NOS3NOS1NOS2HTR1DHTR1B | |
| SCHEMBL709291 | 0.67 | NOS3 (0.40) | NOS3NOS1NOS2HTR1DHTR1B | |
| SCHEMBL11708297 | 0.67 | NOS3 (0.40) | NOS3NOS1NOS2HTR1DHTR1B | |
| SCHEMBL20457709 | 0.67 | — | — | |
| Hydrochloric Acid SCHEMBL3032314 | 0.65 | NOS3 (0.39) | NOS3NOS1NOS2HTR1DHTR1B | |
| Hydrochloric Acid SCHEMBL226047 | 0.65 | NOS3 (0.39) | NOS3NOS1NOS2HTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938256-B2 | Annelated benzamides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-04-10 | — | — | US | disclosed |
| US-20170050952-A1 | NOVEL ANNELATED BENZAMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050952-A1 | NOVEL ANNELATED BENZAMIDES | HDAC10, HDAC11, H1-0 | NOS3 2177/4885NOS1 1610/4885NOS2 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.